Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Subjects With Fatty Acid Oxidation Disorders (FAOD)

NCT03833128 is registered in ClinicalTrials.gov with Reneo Pharma Ltd as lead sponsor.

NCT NCT03833128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Subjects With Fatty Acid Oxidation Disorders (FAOD)
Lead sponsor
Reneo Pharma Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2019
Completion date
March 21, 2022
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fatty acid oxidation disorders